Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice

References

• Reichert JM. Antibodies to watch in 2017. MAbs. 2017;9(2):167–81. doi:10.1080/19420862.2016.1269580. PMID:27960628.
   PubMed Web of Science ®Google Scholar
• Bittner B, Schmidt J. Subcutaneous administration of monoclonal antibodies in oncology as alternative to established intravenous infusion. Pharm Ind. 2012;74:638–43.
   Web of Science ®Google Scholar
• McDonald TA, Zepeda ML, Tomlinson MJ, Bee WH, Ivens IA. Subcutaneous administration of biotherapeutics: current experience in animal models. Curr Opin Mol Ther. 2010;12(4):461–70. PMID:20677097.
   PubMedGoogle Scholar
• Richter WF, Jacobsen B. Subcutaneous (SC) absorption of biotherapeutics – knowns and unknowns. Drug Metab Dispos. 2014;42(11):1881–9. doi:10.1124/dmd.114.059238. PMID:25100673.
   PubMedGoogle Scholar
• Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14:559–70. doi:10.1208/s12248-012-9367-0. PMID:22619041.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–68. doi: 10.1002/jps.20178. doi:10.1002/jps.20178. PMID:15389672.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nature Rev Immunol. 2007;7:715–25. DOI: 10.1038/nri2155. doi:10.1038/nri2155.
   PubMed Web of Science ®Google Scholar
• Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the β2-microglobulin containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA. 1996;93:5512–6. doi:10.1073/pnas.93.11.5512. PMID:8643606.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170(7):3528–33. doi:10.4049/jimmunol.170.7.3528. PMID:12646614.
   PubMed Web of Science ®Google Scholar
• Deng R, Meng YG, Hoyte K, Lutman J, Lu Y Iyer S, DeForge LE, Theil F-P, Fielder PJ, Prabhu S. Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs. 2012;4(1):101–9. doi:10.4161/mabs.4.1.18543. PMID:22327433.
   PubMed Web of Science ®Google Scholar
• Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL. The major histocompatibility complex–related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med. 2003;197(3):315–22. doi:10.1084/jem.20021829. PMID:12566415.
   PubMed Web of Science ®Google Scholar
• Bern M, Sand KM, Nilsen J, Sandlie I, Andersen JT. The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery. J Control Release. 2015;211:144–62. doi:10.1016/j.jconrel.2015.06.006. PMID:26055641.
   PubMed Web of Science ®Google Scholar
• Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the interaction between FcRn and albumin: Opportunities for design of albumin-based therapeutics. Front Immunol. 2015;5:682. doi:10.3389/fimmu.2014.00682. PMID:25674083.
   PubMed Web of Science ®Google Scholar
• Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol 2007;4580–8.
   PubMed Web of Science ®Google Scholar
• Latvala S, Jacobsen B, Otteneder MB, Herrmann A, Kronenberg S. Distribution of FcRn across species and tissues. J Histochem Cytochem. 2017;65(6):321–33. doi:10.1369/0022155417705095. PMID:28402755.
   PubMed Web of Science ®Google Scholar
• Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A. 2008;105(27):9337–42. doi:10.1073/pnas.0801717105. PMID:18599440.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Qiao SW, Yoshida M, Baker K, Lencer WI, Blumberg RS. An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology. 2009;137(5):1746–56. e1. doi:10.1053/j.gastro.2009.07.059. PMID:19664634.
   PubMed Web of Science ®Google Scholar
• Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A. 2009;106(8):2788–93. doi:10.1073/pnas.0810796106.
   PubMed Web of Science ®Google Scholar
• Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J. Immunol. 2001;166:3266–76. doi:10.4049/jimmunol.166.5.3266. PMID:11207281.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, de Haas M, van de Winkel JG. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood. 2006;108(10):3573–9. doi:10.1182/blood-2006-05-024539. PMID:16849638.
   PubMed Web of Science ®Google Scholar
• Borvak J, Richardson J, Medesan C, Antohe F, Radu C, Simionescu M, Ghetie V, Ward ES. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int Immunol. 1998;10(9):1289–98. doi:10.1093/intimm/10.9.1289. PMID:9786428.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548–58. doi:10.1038/clpt.2008.170. PMID:18784655.
   PubMed Web of Science ®Google Scholar
• Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol. 2001; 62:93–105. doi:10.1016/S0198-8859(00)00244-5. PMID:11182218.
   PubMed Web of Science ®Google Scholar
• Fan YY, Neubert H. Quantitative analysis of human neonatal Fc receptor (FcRn) tissue expression in transgenic mice by online peptide immuno-affinity LC-HRMS. Anal Chem. 2016;88(8):4239–47. doi:10.1021/acs.analchem.5b03900. PMID:27012525.
   PubMed Web of Science ®Google Scholar
• Fan YY, Avery LB, Wang M, O'Hara DM, Leung S, Neubert H. Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. MAbs. 2016;8(5):848–53. doi:10.1080/19420862.2016.1178436. PMID:27104806.
   PubMed Web of Science ®Google Scholar
• Powner MB, McKenzie JA, Christianson GJ, Roopenian DC, Fruttiger M. Expression of neonatal Fc receptor in the eye. Invest Ophthalmol Vis Sci. 2014;55(3):1607–15. doi:10.1167/iovs.13-12574. PMID:24550358.
   PubMed Web of Science ®Google Scholar
• Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs. 2013;5(3):397–405. doi:10.4161/mabs.23836.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, Hua F, Jones HM, Neubert H, Polzer RJ, O'Hara DM. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016;8(6):1064–78. doi:10.1080/19420862.2016.1193660. PMID:27232760.
   PubMed Web of Science ®Google Scholar
• Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59. doi:10.2165/11535960-000000000-00000.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Proetzel G, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol. 2016;1438:103–14. doi:10.1007/978-1-4939-3661-8_6. PMID:27150086.
   PubMedGoogle Scholar
• Akilesh S, Huber TB, Wu H, Wang G, Hartleben B, Kopp JB, Miner JH, Roopenian DC, Unanue ER, Shaw AS. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci U S A. 2008;105(3):967–72. doi:10.1073/pnas.0711515105. PMID:18198272.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman SA. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000;89(3):297–310. doi:10.1002/(SICI)1520-6017(200003)89:3%3c297::AID-JPS2%3e3.0.CO;2-P. PMID:10707011.
   PubMed Web of Science ®Google Scholar
• Kagan L, Zhao J, Mager DE. Interspecies pharmacokinetic modeling of subcutaneous absorption of rituximab in mice and rats. Pharm Res. 2014;31(12):3265–73. doi:10.1007/s11095-014-1416-1. PMID:24852895.
   PubMed Web of Science ®Google Scholar
• Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of Monoclonal antibodies: Role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res. 2012;29(2):490–9. doi:10.1007/s11095-011-0578-3. PMID:21887597.
   PubMed Web of Science ®Google Scholar
• Wu F, Tamhane M, Morris ME. Pharmacokinetics, lymph node uptake, and mechanistic PK model of near-infrared dye-labeled bevacizumab after IV and SC administration in mice. AAPS J. 2012;14(2):252–61. doi:10.1208/s12248-012-9342-9. PMID:22391791.
   PubMed Web of Science ®Google Scholar
• Proshina LG. Macrophages of subcutaneous connective tissue after treatment with α -tocopherol and dehydration. Bulletin of Experimental Biology and Medicine (Morphology and pathomorphology) 1998;5:521–4. doi:10.1007/BF02445303.
   Google Scholar
• Fathallah AM, Bankert RB, Balu-Iyer SV. Immunogenicity of subcutaneously administered therapeutic proteins–a mechanistic perspective. AAPS J. 2013;15(4):897–900. doi:10.1208/s12248-013-9510-6. PMID:23856740.
   PubMed Web of Science ®Google Scholar
• Kuan EL, Ivanov S, Bridenbaugh EA, Victora G, Wang W, Childs EW, Platt AM, Jakubzick CV, Mason RJ, Gashev AA, et al. Collecting lymphatic vessel permeability facilitates adipose tissue inflammation and distribution of antigen to lymph node-homing adipose tissue dendritic cells. J Immunol. 2015;194(11):5200–10. doi:10.4049/jimmunol.1500221. PMID:25917096.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, et al. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs. 2012;4(2):243–55. PMID:22453096.
   PubMed Web of Science ®Google Scholar
• Haraya K, Tachibana T, Nezu J. Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metab Pharmacokinet. 2017;32(4):208–17. doi:10.1016/j.dmpk.2017.05.002. PMID:28734646.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808. PMID:14679176.
   PubMed Web of Science ®Google Scholar
• Stein C. Klinische Labordiagnostik und Pharmakokinetik humanisierter therapeutischer Antikörper in human FcRn transgenen Mäusen. DVM thesis 2011, Ludwig-Maximilians-Universität München (https://edoc.ub.uni-muenchen.de/12925/1/Stein_Carsten.pdf).
   Google Scholar
• Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, Allan E, Evans L, Bjørås M, Kjærulff S, Sleep D, Sandlie I, Cameron J. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem. 2014;289(19):13492–502. doi: 10.1074/jbc.M114.549832.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Croy JE, Schirtzinger L, Torgerson S, Breyer M, Wroblewski VJ. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys. MAbs. 2016;8(5):969–82. doi: 10.1080/19420862.2016.1178435.
   PubMed Web of Science ®Google Scholar
• Mordenti J, Rescigno A. Estimation of permeance time, exit time, dilution factor, and steady-state volume of distribution. Pharm Res 1992;9:17–25.
   PubMed Web of Science ®Google Scholar
• Straughn AB. Limitations of noncompartmental pharmacokinetic analysis of biotech drugs. In Meibohm B (editor): Pharmacokinetics and pharmacodynamics of biotech drugs: Principles and case studies in drug development. Wiley-VCH Verlag, Weinheim, 2006.
   Google Scholar
• Chen Y, Balthasar JP. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn; AAPS J. 2012;14(4):850–9. doi:10.1208/s12248-012-9395-9.
   Google Scholar
• Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci. 2003;92(6):1206–15. PMID:12761810.
   PubMed Web of Science ®Google Scholar
• Ferl GZ, Wu AM, DiStefano JJ 3rd. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005;33(11):1640–52. doi:10.1007/s10439-005-7410-3. PMID:16341929.
   PubMed Web of Science ®Google Scholar
• Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn. 2007;34(5):687–709. doi:10.1007/s10928-007-9065-1. PMID:17636457.
   PubMed Web of Science ®Google Scholar
• Xiao JJ. Pharmacokinetic models for FcRn-mediated IgG disposition. J Biomed Biotechnol. 2012;2012:282989. doi:10.1155/2012/282989. PMID:22665983.
   PubMedGoogle Scholar
• Fuhrmann S, Kloft C, Huisinga W. Impact of altered endogenous IgG on unspecific mAb clearance. J Pharmacokinet Pharmacodyn. 2017;44(4):351–74. doi:10.1007/s10928-017-9524-2. PMID:28439684.
   PubMed Web of Science ®Google Scholar
• Li L, Gardner I, Dostalek M, Jamei M. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J. 2014;16(5):1097–109. doi:10.1208/s12248-014-9640-5. PMID:25004823.
   PubMed Web of Science ®Google Scholar
• Niederalt C, Kuepfer L, Solodenko J, Eissing T, Siegmund HU, Block M, Willmann S, Lippert J. A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. J Pharmacokinet Pharmacodyn. 2018;45:235–257. doi:10.1007/s10928-017-9559-4. [Epub ahead of print ].
   PubMed Web of Science ®Google Scholar
• Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al KH, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced halflife of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006;18:1759–69. doi:10.1093/intimm/dxl110. PMID:17077181.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies. Methods Mol Biol 2010;602:93–104. doi:10.1007/978-1-60761-058-8_6. PMID:20012394.
   PubMedGoogle Scholar
• Christianson GJ, Sun VZ, Akilesh S, Pesavento E, Proetzel G, Roopenian DC. Monoclonal antibodies directed against human FcRn and their applications. MAbs. 2012;4(2):208–16. doi:10.4161/mabs.4.2.19397. PMID:22453095.
   PubMed Web of Science ®Google Scholar
• Fronton L, Pilari S, Huisingua W. Monoclonal antibody disposition: a simplified PBPK model and its implications for the derivation and interpretation of classical compartment models. J Pharmacokinet Pharmacodyn. 2014;41:87–107, doi:10.1007/s10928-014-9349-1. PMID:24493102.
   PubMed Web of Science ®Google Scholar
• Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):441–59. doi:10.1016/0010-4809(72)90051-1.
   Google Scholar
• MATLAB and Statistics Toolbox Release 2013b, The MathWorks, Inc., Natick, Massachusetts, United States.
   Google Scholar